#USA #pharmaceuticals #Mahwah #Glenmark #Clindamycin

Glenmark Pharmaceuticals' Latest Launch: Clindamycin Phosphate Foam, 1%

On February 13, 2025, Glenmark Pharmaceuticals Inc., USA, announced the introduction of its new product, Clindamycin Phosphate Foam, 1%. This formulation is designed for topical use and is particularly significant in the treatment of various dermatological conditions caused by bacteria.

Clindamycin Phosphate Foam is said to be bioequivalent and therapeutically equivalent to the reference product, Evoclin® Foam, 1%, manufactured by Mylan Pharmaceuticals Inc. According to the latest IQVIA™ sales data, Evoclin® Foam achieved approximately $5.8 million in annual sales during the year leading up to December 2024, highlighting the potential market demand for Clindamycin Phosphate Foam now that it’s available as a competitive option.

The Benefits of Clindamycin Phosphate Foam

Clindamycin is widely recognized for its effectiveness in managing severe skin conditions, including acne and other bacterial infections. Glenmark's foam formulation offers unique advantages:

• - Ease of Application: The foam is lightweight and easy to apply, providing convenience for patients.
• - Quick Absorption: The product's formulation allows for rapid absorption into the skin, which is beneficial for immediate therapeutic effects.
• - Targeted Treatment: The specificity of Clindamycin towards bacterial infections minimizes the side effects compared to broader-spectrum antibiotics.

Given these benefits, Glenmark anticipates that Clindamycin Phosphate Foam will fill a crucial gap in patient care by providing an effective solution for managing skin ailments.

Glenmark Pharmaceuticals: An Overview

Glenmark Pharmaceuticals Ltd., incorporated in India, has established itself as a notable player in the global pharmaceutical market. With a strong commitment to research and development, the company focuses primarily on major therapeutic areas, including dermatology, oncology, and respiratory diseases. Glenmark manufactures a range of products across branded, generic, and over-the-counter segments through its impressive network of 11 state-of-the-art manufacturing facilities worldwide, as well as operations in over 80 countries.

In 2023, Glenmark earned a spot in the Top 100 biopharmaceutical companies, as ranked by Pharmaceutical Sales. Moreover, it also ranked among the Top 50 Generics and Biosimilar companies in 2024, according to Generics Bulletin. A testament to its sustainability efforts, Glenmark’s greenhouse gas emission reduction targets have received validation from the Science Based Target initiative (SBTi), making it a pioneer as only the second pharmaceutical company in India to achieve such recognition.

Looking Ahead

As Glenmark Pharmaceuticals continues to innovate within the health sector, the launch of Clindamycin Phosphate Foam stands as a promising addition to its growing portfolio. The company's dedication to enhancing patient care through effective pharmaceutical products is mirrored by its notable CSR activities, having impacted over 3.3 million lives through various initiatives over the past decade.

For more information about Glenmark Pharmaceuticals and their latest developments, visit their official website at www.glenmarkpharma.com. Follow them on LinkedIn (@Glenmark Pharmaceuticals) and Instagram (@glenmark_pharma) for updates.